Brought to you by 
Pfizer gains exclusive rights to Protalix's Gaucher candidate
30 Jan 2023
Executive Summary
Protalix (develops recombinant therapeutic proteins) has licensed Pfizer exclusive worldwide rights--with the exception of Israel where Protalix is based and retains rights--to commercialize Uplyso (taliglucerase alfa) for Gaucher's disease, an inherited lysosomal storage disorder.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer gains exclusive rights to Protalix's Gaucher candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice